TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31786367

Group type: EXPERIMENTAL
Intervention: High vowel overlap training (e.g., EA, AI)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Low vowel overlap training (e.g., EE, AI)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Consonant variability manipulation
Number of subjects: 361
Study: 29844205

Group type: EXPERIMENTAL
Intervention: BuFlu
Number of subjects: 1781

Group type: COMPARATOR
Intervention: BuCy
Number of subjects: 1781
Study: 28122649

Group type: EXPERIMENTAL
Intervention: L- and MZ-enriched eggs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control non-enriched eggs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (enriched and control)
Number of subjects: 0
Study: 25692545

Group type: EXPERIMENTAL
Intervention: Hemosep device
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (unprocessed blood)
Number of subjects: 53
Study: 23725103

Group type: EXPERIMENTAL
Intervention: Perceived parental attitudes
Number of subjects: 250
Study: 20350251

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 50 mg/day
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Beta-carotene 20 mg/day
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1700
Study: 17625985

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI (80/4.5 microg)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: formoterol DPI (4.5 microg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: budesonide pMDI (80 microg) alone
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI and formoterol DPI
Number of subjects: 201
Study: 16584339

Group type: EXPERIMENTAL
Intervention: Conventional periodontal scaling and root planing
Number of subjects: 0
Study: 15094102

Group type: EXPERIMENTAL
Intervention: Oral amino acid mixture (OAAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11922397

Group type: COMPARATOR
Intervention: Promethazine (PRM) 30 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levocetirizine (L-CTZ) 5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetirizine (CTZ) 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Loratadine (LOR) 10 mg
Number of subjects: 20
Study: 9517644

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 250 mg q.i.d.
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d. and metronidazole 400 mg b.i.d. for the first 2 wk
Number of subjects: 648
Study: 8050457

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DU)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Strain gauge plethysmography (SGP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Various combinations of cuff/strain gauge positioning
Number of subjects: 25
Study: 3046814

Group type: EXPERIMENTAL
Intervention: guanabenz
Number of subjects: 218

Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Number of subjects: 218
Study: 29701288

Group type: EXPERIMENTAL
Intervention: BAHS implantation using minimally invasive Ponto surgery technique
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BAHS implantation using linear incision technique with soft‐tissue preservation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Inflammation episodes
Number of subjects: 35
Study: 28502243

Group type: EXPERIMENTAL
Intervention: Targeted training in illness management (TTIM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study: 24118914

Group type: EXPERIMENTAL
Intervention: Immediate occlusal loading
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-occlusal loading (control)
Number of subjects: 19
Study: 24160371

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for prolapse
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: A process for Decision-making after Pilot and feasibility Trials (ADePT)
Number of subjects: 50
Study: 21949149

Group type: EXPERIMENTAL
Intervention: Rapid nasogastric rehydration (RNR) over 4 hours in the ED
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard nasogastric rehydration (SNR) over 24 hours in the hospital ward
Number of subjects: 254
Study: 18382339

Group type: EXPERIMENTAL
Intervention: Low boric acid-containing rewetting drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High boric acid-containing rewetting drops
Number of subjects: 0
Study: 16873325

Group type: EXPERIMENTAL
Intervention: Usual conservative treatment (UT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: UT plus a conventional flat-plane hard acrylic splint (HS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: UT plus a soft vinyl splint (SS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: HS versus SS
Number of subjects: 200

Group type: COMPARATOR
Intervention: Self-care treatment without splint therapy (UT)
Number of subjects: 200
Study: 12644522

Group type: EXPERIMENTAL
Intervention: Lateral‐medial area index
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lateral‐medial force index
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lateral‐medial area index and lateral‐medial force index
Number of subjects: 105
Study: 10672051

Group type: EXPERIMENTAL
Intervention: PCM-7 (7 days of pantoprazole 40 mg bid, clarithromycin 500 mg bid, metronidazole 500 mg bid)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PCM-14 m (modified 14 day therapy with metronidazole only given for 10 days)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both PCM-7 and PCM-14 m
Number of subjects: 213
Study: 9280742

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 100 mg p.o. or i.m. for moderate to intense pain
Number of subjects: 102
Study: 8149141

Group type: EXPERIMENTAL
Intervention: 200 mg acyclovir orally four times daily during induction therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 3521240

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dipyrone 575 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Tartrazine 50 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 3
Study: 29498050

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy plus antimicrobials
Number of subjects: 114

Group type: COMPARATOR
Intervention: Antimicrobials alone
Number of subjects: 114
Study: 27687354

Group type: EXPERIMENTAL
Intervention: Prone position (P)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sitting position (S)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Flexed lateral position (L)
Number of subjects: 78
Study: 24757084

Group type: EXPERIMENTAL
Intervention: Ivabradine (Iva) 5 mg BID
Number of subjects: 334

Group type: COMPARATOR
Intervention: Atenolol (Aten) 12.5 mg BID
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Ivabradine (Iva)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Atenolol (Aten)
Number of subjects: 334
Study: 22493914

Group type: EXPERIMENTAL
Intervention: Aconite cake-separated moxibustion therapy with acupoints (Danzhong (CV 17), Zhongwan (CV 12), Guanyuan (CV 4), Dazhui (GV 14), Shenshu (BL 23), Mingmen (GV 4)) and oral administration of 25 microg Euthyrox everyday
Number of subjects: 85

Group type: COMPARATOR
Intervention: Oral administration of 25 microg Euthyrox everyday
Number of subjects: 85
Study: 20537841

Group type: EXPERIMENTAL
Intervention: Mass media interventions consisting of specially developed messages based on behavioral theory targeted to defined age groups, placed in popular TV, cable, and radio programming for 4 years.
Number of subjects: 19966

Group type: EXPERIMENTAL
Intervention: Mass media interventions
Number of subjects: 19966

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19966
Study: 19053917

Group type: COMPARATOR
Intervention: DFDBA alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: DFDBA combined with EMD
Number of subjects: 32
Study: 15672076

Group type: EXPERIMENTAL
Intervention: JC‐EUS
Number of subjects: 40

Group type: COMPARATOR
Intervention: C‐EUS
Number of subjects: 40
Study: 12826990

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acamprosate 2 g/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acamprosate 3 g/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined treatment (Naltrexone and Acamprosate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naltrexone and Acamprosate (both alone and in combination)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined medications
Number of subjects: 23
Study: 10821210

Group type: EXPERIMENTAL
Intervention: Day-long ad lib smoking session
Number of subjects: 25

Group type: COMPARATOR
Intervention: Overnight smoking abstinence session
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alcohol pre-load (9 oz or 270 ml of beer)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Smoking session
Number of subjects: 25
Study: 8888301

Group type: EXPERIMENTAL
Intervention: Superordinate relationships affecting perceptual judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual distortions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propositional rules
Number of subjects: 0
Study: 1710922

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with eight cycles of MOPP
Number of subjects: 192

Group type: COMPARATOR
Intervention: Combination of MOPP and ABVD
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Radiotherapy after partial response
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Overall treatment (including both arms)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Treatment of relapsed patients
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Complete remission (achieved by any means)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Progression of disease
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Relapses
Number of subjects: 192
Study: 6634077

Group type: EXPERIMENTAL
Intervention: High intensity light
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lower illumination
Number of subjects: 133
Study: 31441863

Group type: EXPERIMENTAL
Intervention: Infrared laser moxibustion (ILM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham infrared laser moxibustion (SILM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 0
Study: 29370829

Group type: EXPERIMENTAL
Intervention: Text4Heart II intervention (24-week personalized text message program)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study: 27422220

Group type: EXPERIMENTAL
Intervention: US-guided IV placement
Number of subjects: 59

Group type: COMPARATOR
Intervention: SOC palpation IV technique
Number of subjects: 59
Study: 24112096

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone induction
Number of subjects: 69
Study: 21942692

Group type: EXPERIMENTAL
Intervention: First-line antiretroviral (ARV) treatment
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Second-line regimen proposed by WHO (2010) including zidovudine, tenofovir, lopinavir, and atazanavir
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Genotypic resistance testing
Number of subjects: 386
Study: 21119104

Group type: COMPARATOR
Intervention: Chest radiograph screening
Number of subjects: 53456

Group type: EXPERIMENTAL
Intervention: Computerized tomography screening
Number of subjects: 53456
Study: 17559147

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with elevated serum HER-2/neu levels (>15 ng/mL) before treatment
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with elevated serum HER-2/neu levels at 2 months
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with changes in HER-2/neu levels between baseline and 2 months
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with >or=20% increase of serum HER-2/neu
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with kinetics of serum HER-2/neu
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with low baseline serum levels of EGFR (<45 ng/mL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with low baseline serum levels of EGFR
Number of subjects: 135
Study: 16618317

Group type: EXPERIMENTAL
Intervention: Versajet Hydrosurgery System
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional debridement with moist dressings
Number of subjects: 68
Study: 11955464

Group type: EXPERIMENTAL
Intervention: Yohimbine (.4 mg/kg, IV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 17
Study: 10691066

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 15000
Study: 9484152

Group type: EXPERIMENTAL
Intervention: Ceramic tooth simulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural tooth simulator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dexterity students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOD onlay preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceramic teeth
Number of subjects: 0
Study: 1555273

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg/day
Number of subjects: 8245
Study: 3926042

Group type: EXPERIMENTAL
Intervention: Infusion of morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 30894587

Group type: EXPERIMENTAL
Intervention: Conventional MRI measurements
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: DWI MRI measurements
Number of subjects: 236

Group type: COMPARATOR
Intervention: Conventional model with DWI measurements
Number of subjects: 236
Study: 29292308

Group type: EXPERIMENTAL
Intervention: AAR and telephone-based behavioral counseling
Number of subjects: 327

Group type: COMPARATOR
Intervention: AAR and attention control (nutrition education)
Number of subjects: 327
Study: 27006306

Group type: EXPERIMENTAL
Intervention: Psychological skills training (D6)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control intervention (no psychological element)
Number of subjects: 23
Study: 24881497

Group type: EXPERIMENTAL
Intervention: Nonantibiotic, alcohol-based antiseptic
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study: 22245769

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4)) administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transdermal estradiol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20297613

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (5 mg/325 mg, titrated for pain relief)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (mean daily dose 13.8 mg/720.4 mg)
Number of subjects: 29
Study: 18685961

Group type: EXPERIMENTAL
Intervention: Intrathecal thoracic analgesia (ITA) with levobupivacaine 0.25%, at 0.5-0.7 ml/h, and a single bolus of morphine 0.15 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural thoracic analgesia (ETA) with levobupivacaine 0.25% 4-6 ml/h and a single bolus of epidural morphine 2-3 mg
Number of subjects: 60
Study: 15741443

Group type: EXPERIMENTAL
Intervention: Fluticasone 500 mug twice daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 12515837

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (6 weekly sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Supportive psychotherapy (6 weekly sessions)
Number of subjects: 61
Study: 10916110

Group type: EXPERIMENTAL
Intervention: Hydrosoluble vitamins (DiaVite) supplementation once daily by mouth
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week) in addition to DiaVite
Number of subjects: 168

Group type: COMPARATOR
Intervention: Hydrosoluble vitamins (DiaVite) supplementation
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week)
Number of subjects: 168
Study: 8873685

Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg b.i.d. for 7 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg q.i.d. for 7 days)
Number of subjects: 15
Study: 1647387

Group type: EXPERIMENTAL
Intervention: Interactive information system with instructional video programs, feedback on purchases, specific goals for change, weekly programs, and tracking user interactions; duration: 7-8 weeks intervention phase after a 5-7 week baseline phase.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition; duration: 7-8 weeks intervention phase after a 5-7 week baseline phase.
Number of subjects: 0
Study: 30183743

Group type: EXPERIMENTAL
Intervention: Rifaximin‐α (n = 36)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 54
Study: 27287439

Group type: EXPERIMENTAL
Intervention: Ovaleap® (recombinant human follicle-stimulating hormone) administered for up to 2 additional cycles
Number of subjects: 208
Study: 24561149

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 699
Study: 22278714

Group type: EXPERIMENTAL
Intervention: Pre-operative examination with cervical traction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pre-operative examination without cervical traction
Number of subjects: 81
Study: 20544673

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 78

Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 78
Study: 18391711

Group type: EXPERIMENTAL
Intervention: Meperidine-impregnated autogenous free fat grafts (AFFGs) in the epidural area
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group received graft without meperidine impregnation
Number of subjects: 27
Study: 15984397

Group type: EXPERIMENTAL
Intervention: System E (gelatin/pectin-based skin barrier with adhesive coupling technology)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: System E
Number of subjects: 39

Group type: COMPARATOR
Intervention: System F (grooved base plate wafer adhesive pouch coupling system)
Number of subjects: 39
Study: 12795776

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10325838

Group type: EXPERIMENTAL
Intervention: Neostigmine in patients pretreated with MgSO4 (group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neostigmine in patients receiving saline (group B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Assisted recovery in MgSO4 pretreated patients (group C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Assisted recovery in controls (group D)
Number of subjects: 12
Study: 8953337

Group type: EXPERIMENTAL
Intervention: 6.9% glucose-polymer (GP) solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1745853

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6886965

Group type: EXPERIMENTAL
Intervention: Alcohol (low dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonalcoholic beverage (tonic water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructional set (regardless of drink content)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locus of control (externalizers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locus of control (internalizers)
Number of subjects: 0
Study: 31813942

Group type: EXPERIMENTAL
Intervention: Equia Fil/Equia Coat
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fuji IX GP Fast/Fuji Coat LC
Number of subjects: 34
Study: 29858504

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 51
Study: 27240816

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Nutritional intervention including exposure to posters and distribution of pamphlets to parents with recipes and information about healthy foods.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention.
Number of subjects: 0
Study: 24492628

Group type: EXPERIMENTAL
Intervention: Postoperative drainage with one chest tube (PD1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Postoperative drainage with two chest tubes (PD2)
Number of subjects: 108
Study: 22713773

Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day) in BEAN1
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: High-soy diet (2 servings/day) in BEAN2
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (low-soy diet <3 servings/week) in BEAN1
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (low-soy diet <3 servings/week) in BEAN2
Number of subjects: 267
Study: 20663148

Group type: EXPERIMENTAL
Intervention: Aerobic training (n = 18)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Strength-based training (n = 14)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 63